Neel Gandhi, M.D., is a physician-scientist at Emory's Rollins School of Public Health with 80% effort dedicated to patient-oriented research (POR). He seeks funding through the K24 Midcareer Investigator Award to expand his POR program in drug-resistant tuberculosis (TB), HIV and global health, and to mentor clinical investigators in these areas. The intersection between drug-resistant TB and HIV is an emerging global public health issue which threatens a decade of gains in TB control. There is a growing need for innovative research in TB genomics, immunology, and therapeutics, in addition to developing a pool of scientists trained in TB/HIV and global health POR. Dr. Gandhi has demonstrated a commitment to clinical, epidemiologic and translational research in TB/HIV and global health over the past decade, including a strong record of successfully mentoring 24 trainees, to date. Emory University provides a robust environment for training clinical investigators through its degree programs (MPH, MS, PhD), post-doctoral fellowships and multi-disciplinary centers (CTSA, CFAR, Global Health). Within this highly conducive training environment, Dr. Gandhi has created a comprehensive mentoring program that focuses on the design and responsible conduct of hypothesis-driven research to assist trainees in becoming independent investigators. This K24 award will greatly facilitate the PI's immediate and long-term career goals, which include to: 1) Understand how whole genome sequencing can further elucidate mechanisms of acquired resistance and transmission in drug- resistant TB epidemics; 2) Advance his knowledge of human immunology to inform future studies of increased TB susceptibility among HIV-infected individuals; 3) Expand clinical trials skills to facilitate the design and implementation of drug-resistant TB and TB/HIV trials; and 4) Enhance the structure and content of his mentorship of trainees pursuing careers in patient- oriented TB, HIV and Global Health research. This award will utilize a framework of multiple NIH-funded studies in drug-resistant TB and HIV in South Africa to investigate two novel specific research aims: 1) To examine polymorphisms in the M.tuberculosis genome which arise among MDR TB subjects who develop additional resistance on treatment, and 2) To investigate the incremental yield of whole genome sequencing in identifying micro-clusters of XDR TB transmission in large genotypic clusters. The K24 award will allow Dr. Gandhi to continue his highly-successful research program in TB, HIV and global health, and mentor the next generation of investigators in this vital research field.

Public Health Relevance

The intersection between drug-resistant TB and HIV is a growing global public health issue which threatens a decade of gains in TB control. Neel Gandhi, M.D., is a physician-scientist at Emory's Rollins School of Public Health dedicated to patient-oriented research in TB, HIV and global health. The K24 award will provide the needed protected time for Dr. Gandhi to provide mentorship to young investigators pursuing these fields and to expand his research program in the emerging areas of TB genomics, immunology and clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
5K24AI114444-05
Application #
9489155
Study Section
Acquired Immunodeficiency Syndrome Research Review Committee (AIDS)
Program Officer
Srinivasan, Sudha
Project Start
2014-06-01
Project End
2019-05-31
Budget Start
2018-06-01
Budget End
2019-05-31
Support Year
5
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Emory University
Department
Public Health & Prev Medicine
Type
Schools of Public Health
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Haddad, Maryam B; Raz, Kala M; Lash, Timothy L et al. (2018) Simple Estimates for Local Prevalence of Latent Tuberculosis Infection, United States, 2011-2015. Emerg Infect Dis 24:1930-1933
Auld, Sara C; Shah, N Sarita; Cohen, Ted et al. (2018) Where is tuberculosis transmission happening? Insights from the literature, new tools to study transmission and implications for the elimination of tuberculosis. Respirology :
Magee, M J; Gandhi, N R; Kornfeld, H (2018) A dual purpose for household contact investigations: preventing TB disease and improving diabetes outcomes. Int J Tuberc Lung Dis 22:594-595
Nelson, Kristin N; Shah, N Sarita; Mathema, Barun et al. (2018) Spatial Patterns of Extensively Drug-Resistant Tuberculosis Transmission in KwaZulu-Natal, South Africa. J Infect Dis 218:1964-1973
Bozio, Catherine H; Flanders, W Dana; Finelli, Lyn et al. (2018) Use of Multiple Imputation to Estimate the Proportion of Respiratory Virus Detections Among Patients Hospitalized With Community-Acquired Pneumonia. Open Forum Infect Dis 5:ofy061
Peloquin, Charles A; Phillips, Patrick P J; Mitnick, Carole D et al. (2018) Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis. Antimicrob Agents Chemother 62:
Auld, Sara C; Shah, N Sarita; Mathema, Barun et al. (2018) Extensively drug-resistant tuberculosis in South Africa: genomic evidence supporting transmission in communities. Eur Respir J 52:
Brust, James C M; Shah, N Sarita; Mlisana, Koleka et al. (2018) Improved Survival and Cure Rates With Concurrent Treatment for Multidrug-Resistant Tuberculosis-Human Immunodeficiency Virus Coinfection in South Africa. Clin Infect Dis 66:1246-1253
Auld, Sara C; Kasmar, Anne G; Dowdy, David W et al. (2017) Research Roadmap for Tuberculosis Transmission Science: Where Do We Go From Here and How Will We Know When We're There? J Infect Dis 216:S662-S668
Magee, Matthew J; Sun, Yan V; Brust, James C M et al. (2017) Polymorphisms in the vitamin D receptor gene are associated with reduced rate of sputum culture conversion in multidrug-resistant tuberculosis patients in South Africa. PLoS One 12:e0180916

Showing the most recent 10 out of 32 publications